Dronabinol can be approved to deal with anorexia and weightloss affiliated with HIV/AIDS. The FDA has also approved a plant derived cannabidiol-centered medication to deal with seizures related to uncommon forms of epilepsy.In 2024, the U.S. Drug Enforcement Administration (DEA) indicated which they intend to reclassify cannabis being a Schedule II